X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ELDER PHARMA VENUS REMEDIES/
ELDER PHARMA
 
P/E (TTM) x -3.4 -0.2 - View Chart
P/BV x 0.1 0.1 125.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   ELDER PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ELDER PHARMA
Jun-14
VENUS REMEDIES/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs126380 33.1%   
Low Rs61188 32.5%   
Sales per share (Unadj.) Rs301.8491.2 61.4%  
Earnings per share (Unadj.) Rs-24.9-3.2 781.7%  
Cash flow per share (Unadj.) Rs2.514.4 17.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.3376.5 77.9%  
Shares outstanding (eoy) m12.3420.54 60.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.6 53.6%   
Avg P/E ratio x-3.8-89.3 4.2%  
P/CF ratio (eoy) x36.719.7 186.4%  
Price / Book Value ratio x0.30.8 42.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,1545,833 19.8%   
No. of employees `0000.9NA-   
Total wages/salary Rs m3932,179 18.0%   
Avg. sales/employee Rs Th4,026.1NM-  
Avg. wages/employee Rs Th425.0NM-  
Avg. net profit/employee Rs Th-331.8NM-  
INCOME DATA
Net Sales Rs m3,72410,089 36.9%  
Other income Rs m23257 8.8%   
Total revenues Rs m3,74710,346 36.2%   
Gross profit Rs m395-792 -49.9%  
Depreciation Rs m338361 93.6%   
Interest Rs m3542,756 12.9%   
Profit before tax Rs m-275-3,653 7.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m32125 25.2%   
Profit after tax Rs m-307-65 469.6%  
Gross profit margin %10.6-7.8 -135.1%  
Effective tax rate %-11.5-3.4 335.0%   
Net profit margin %-8.2-0.6 1,272.3%  
BALANCE SHEET DATA
Current assets Rs m2,6389,240 28.5%   
Current liabilities Rs m2,3059,998 23.1%   
Net working cap to sales %8.9-7.5 -119.1%  
Current ratio x1.10.9 123.8%  
Inventory Days Days13546 292.5%  
Debtors Days Days4660 77.3%  
Net fixed assets Rs m4,87110,124 48.1%   
Share capital Rs m123206 60.0%   
"Free" reserves Rs m3,4965,582 62.6%   
Net worth Rs m3,6197,734 46.8%   
Long term debt Rs m1,3744,889 28.1%   
Total assets Rs m7,50922,882 32.8%  
Interest coverage x0.2-0.3 -68.5%   
Debt to equity ratio x0.40.6 60.1%  
Sales to assets ratio x0.50.4 112.5%   
Return on assets %0.611.8 5.4%  
Return on equity %-8.5-0.8 1,003.5%  
Return on capital %1.622.3 7.1%  
Exports to sales %03.0 0.0%   
Imports to sales %13.90.4 3,246.8%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs m51743 1,198.5%   
Fx inflow Rs m0307 0.0%   
Fx outflow Rs m517125 412.2%   
Net fx Rs m-517181 -284.9%   
CASH FLOW
From Operations Rs m51411,754 4.4%  
From Investments Rs m-123-561 22.0%  
From Financial Activity Rs m-387-6,762 5.7%  
Net Cashflow Rs m44,432 0.1%  

Share Holding

Indian Promoters % 32.9 39.6 83.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 7.5 2.4%  
FIIs % 0.6 16.8 3.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 36.1 183.9%  
Shareholders   20,121 16,479 122.1%  
Pledged promoter(s) holding % 36.4 77.6 46.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 15, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ALEMBIC PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS